Steering Evolution with Sequential Therapy to Prevent the Emergence of Bacterial Antibiotic Resistance

PLoS Computational Biology

Volumn 11, Issue 9, 2015, Pages

  Nichol, Daniel ^a,b   Jeavons, Peter ^a   Fletcher, Alexander G ^a   Bonomo, Robert A ^c   Maini, Philip K ^a   Paul, Jerome L ^d   Gatenby, Robert A ^b   Anderson, Alexander R A ^b   Scott, Jacob G ^a,b  

^a UNIVERSITY OF OXFORD   (United Kingdom)

^b H LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE   (United States)

^c VETERANS AFFAIRS MEDICAL CENTER   (United States)

^d UNIVERSITY OF CINCINNATI   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DRUG THERAPY; ESCHERICHIA COLI; HEALTH RISKS; MARKOV PROCESSES;

ALGEBRAIC PROPERTIES; ANTIBIOTIC TREATMENT; ANTIBIOTICS RESISTANCE; BACTERIAL ANTIBIOTIC RESISTANCE; BIASED RANDOM WALK; CHAIN TRANSITIONS; FITNESS LANDSCAPE; GLOBAL PROPERTIES; NOVEL ANTIBIOTICS; SIMPLE MODELING;

ANTIBIOTICS;

BETA LACTAM ANTIBIOTIC; ANTIINFECTIVE AGENT;

ANTIBIOTIC RESISTANCE; ARTICLE; ASEXUAL REPRODUCTION; BACTERIAL STRAIN; ESCHERICHIA COLI; EVOLUTIONARY ADAPTATION; GENOTYPE; MATHEMATICAL MODEL; MOLECULAR EVOLUTION; NATURAL SELECTION; NONHUMAN; PREDICTION; PROBABILITY; BIOLOGICAL MODEL; BIOLOGY; DRUG EFFECTS; ESCHERICHIA COLI INFECTION; GENETIC SELECTION; GENETICS; HUMAN; MICROBIOLOGY; REPRODUCTIVE FITNESS;

ANTI-BACTERIAL AGENTS; COMPUTATIONAL BIOLOGY; DRUG RESISTANCE, BACTERIAL; ESCHERICHIA COLI; ESCHERICHIA COLI INFECTIONS; EVOLUTION, MOLECULAR; GENETIC FITNESS; HUMANS; MODELS, BIOLOGICAL; SELECTION, GENETIC;

EID: 84943537607     PISSN: 1553734X     EISSN: 15537358     Source Type: Journal    
DOI: 10.1371/journal.pcbi.1004493     Document Type: Article

References (74)

1. Spellberg B, Bartlett JG, Gilbert DN, The future of antibiotics and resistance. N Engl J Med. 2013 Jan 24;368(4):299–302. doi: 10.1056/NEJMp1215093 23343059
2. French GL, The continuing crisis in antibiotic resistance. Int J Antimicrob Agents. 2010 Nov;36 Suppl 3:S3–7. doi: 10.1016/S0924-8579(10)70003-0 21129629
3. Silver LL, Challenges of antibacterial discovery. Clin Microbiol Rev. 2011 Jan;24(1):71–109. 21233508
4. Shlaes DM, Gerding DN, John JF, Craig WA, Bornstein DL, Duncan RA, et al. Society for Healthcare Epidemiology of America and Infectious Diseases Society of America Joint Committee on the Prevention of Antimicrobial Resistance: guidelines for the prevention of antimicrobial resistance in hospitals. Infect Control Hosp Epidemiol. 1997 Apr;18(4):275–91. doi: 10.1086/647610 9131374
5. Bartlett JG, A call to arms: the imperative for antimicrobial stewardship. Clin Infect Dis. 2011 Aug;53 Suppl 1:S4–7. doi: 10.1093/cid/cir362 21795727
6. Leuthner KD, Doern GV, Antimicrobial stewardship programs. J Clin Microbiol. 2013 Dec;51(12): 3916–3920. 23926165
7. Mathew AG, Cissell R, Liamthong S, Antibiotic resistance in bacteria associated with food animals: a United States perspective of livestock production. Foodborne Pathog Dis. 2007 Summer;4(2):115–33. doi: 10.1089/fpd.2006.0066 17600481
8. Moody J, Cosgrove SE, Olmsted R, Septimus E, Aureden K, Oriola S, et al. Antimicrobial stewardship: a collaborative partnership between infection preventionists and healthcare epidemiologists. Am J Infect Control. 2012 Mar;40(2):94–5. doi: 10.1016/j.ajic.2012.01.001 22381221
9. Chait R, Craney A, Kishony R, Antibiotic interactions that select against resistance. Nature. 2007 Apr 5;446(7136):668–71. doi: 10.1038/nature05685 17410176
10. Munck C, Gumpert HK, Wallin AI, Wang HH, Sommer MO, Prediction of resistance development against drug combinations by collateral responses to component drugs. Sci Transl Med. 2014 Nov 12;6(262):262ra156. doi: 10.1126/scitranslmed.3009940 25391482
11. de Evgrafov MR, Gumpert H, Munck C, Thomsen TT, Sommer MO, Collateral resistance and sensitivity modulate evolution of high-level resistance to drug combination treatment in Staphylococcus aureus. Mol Biol Evol. 2015 May;32(5):1175–85. doi: 10.1093/molbev/msv006
12. Gatenby RA, Silva AS, Gillies RJ, Frieden BR, Adaptive therapy. Cancer Res. 2009 Jun 1;69(11):4894–903. 19487300
13. Coldman AJ, Goldie JH, A model for the resistance of tumor cells to cancer chemotherapeutic agents. Math Biosci. 1983;65(2):291–307. doi: 10.1016/0025-5564(83)90066-4
14. Day RS, Treatment sequencing, asymmetry, and uncertainty: protocol strategies for combination chemotherapy. Cancer Res. 1986 Aug;46(8):3876–85. 3731062
15. Katouli AA, Komarova NL, The worst drug rule revisited: mathematical modeling of cyclic cancer treatments. Bull Math Biol. 2011 Mar;73(3):549–84. doi: 10.1007/s11538-010-9539-y 20396972
16. Sanga S, Sinek JP, Frieboes HB, Ferrari M, Fruehauf JP, Cristini V, Mathematical modeling of cancer progression and response to chemotherapy. Expert Rev Anticancer Ther. 2006 Oct;6(10):1361–76. doi: 10.1586/14737140.6.10.1361 17069522
17. Byrne HM, Alarcon T, Owen M, Webb SD, Maini PK, Modelling aspects of cancer dynamics: a review. Philos Trans A Math Phys Eng Sci. 2006 Jun 15;364(1843):1563–78. doi: 10.1098/rsta.2006.1786 16766361
18. Bellomo N, Li NK, Maini PK, On the foundations of cancer modelling: selected topics, speculations, and perspectives. Math Models Methods Appl Sci. 2008;18(04):593–646. doi: 10.1142/S0218202508002796
19. Swierniak A, Kimmel M, Smieja J, Mathematical modeling as a tool for planning anticancer therapy. Eur J Pharmacol. 2009 Dec 25;625(1–3):108–21. doi: 10.1016/j.ejphar.2009.08.041 19825370
20. Deisboeck TS, Zhang L, Yoon J, Costa J, In silico cancer modeling: is it ready for prime time? Nat Clin Pract Oncol. 2009 Jan;6(1):34–42. doi: 10.1038/ncponc1237 18852721
21. Goulart CP, Mahmudi M, Crona KA, Jacobs SD, Kallmann M, Hall BG, et al. Designing antibiotic cycling strategies by determining and understanding local adaptive landscapes. PLoS One. 2013;8(2):e56040. doi: 10.1371/journal.pone.0056040 23418506
22. Bergstrom CT, Lo M, Lipsitch M, Ecological theory suggests that antimicrobial cycling will not reduce antimicrobial resistance in hospitals. Proc Natl Acad Sci U S A 2004;101(36):13285–13290. doi: 10.1073/pnas.0402298101 15308772
23. Pena-Miller R, Beardmore RE, Antibiotic cycling versus mixing: the difficulty of using mathematical models to definitively quantify their relative merits. Math Biosci Eng 2010 Oct;7(4):923–33. doi: 10.3934/mbe.2010.7.923 21077716
24. Bonhoeffer S, zur Wiesch PA, Kouyos RD, Rotating antibiotics does not minimize selection for resistance. Math Biosci Eng. 2010 Oct;7(4):919–22. doi: 10.3934/mbe.2010.7.919 21077715
25. zur Wiesch PA, Kouyos R, Abel S, Viechtbauer W, Bonhoeffer S, Cycling empirical antibiotic therapy in hospitals: meta-analysis and models. PLoS Pathog. 2014 Jun 26;10(6):e1004225. doi: 10.1371/journal.ppat.1004225
26. de Visser JAGM, Krug J, Empirical fitness landscapes and the predictability of evolution. Nat Rev Genet. 2014 Jul;15(7):480–90. doi: 10.1038/nrg3744 24913663
27. Weinreich DM, Watson RA, Chao L, Perspective: sign epistasis and genetic constraint on evolutionary trajectories. Evolution. 2005 Jun;59(6):1165–74. doi: 10.1111/j.0014-3820.2005.tb01768.x 16050094
28. Weinreich DM, Delaney NF, DePristo MA, Hartl DL, Darwinian evolution can follow only very few mutational paths to fitter proteins. Science. 2006 Apr 7;312(5770):111–4. doi: 10.1126/science.1123539 16601193
29. Tan L, Serene S, Chao HX, Gore J, Hidden randomness between fitness landscapes limits reverse evolution. Phys Rev Lett. 2011 May 13;106(19):198102 doi: 10.1103/PhysRevLett.106.198102 21668204
30. zur Wiesch PS, Engelstädter J, Bonhoeffer S, Compensation of fitness costs and reversibility of antibiotic resistance mutations. Antimicrob Agents Chemother. 2010 May;54(5):2085–95.
31. Tanaka MM, Valckenborgh F, Escaping an evolutionary lobster trap: drug resistance and compensatory mutation in a fluctuating environment. Evolution. 2011 May;65(5):1376–87. doi: 10.1111/j.1558-5646.2011.01223.x 21521192
32. Imamovic L, Sommer MO, Use of collateral sensitivity networks to design drug cycling protocols that avoid resistance development. Sci Transl Med. 2013 Sep 25;5(204):204ra132. doi: 10.1126/scitranslmed.3006609 24068739
33. Mira PM, Crona K, Greene D, Meza JC, Sturmfels B, Barlow M, Rational Design of Antibiotic Treatment Plans: A Treatment Strategy for Managing Evolution and Reversing Resistance. PLoS One. 2015 May 6;10(5):e0122283. doi: 10.1371/journal.pone.0122283 25946134
34. Gillespie JH, A simple stochastic gene substitution model. Theor Popul Biol. 1983 Apr;23(2):202–15. doi: 10.1016/0040-5809(83)90014-X 6612632
35. Gillespie JH, Molecular evolution over the mutational landscape. Evolution. 1984 Sep; 38(5): 1116–1129. doi: 10.2307/2408444
36. Kauffman SA, Levin S, Towards a general theory of adaptive walks on rugged landscapes. J Theor Biol. 1987 Sep 7;128(1):11–45. doi: 10.1016/S0022-5193(87)80029-2 3431131
37. Kauffman SA, Weinberger ED, The NK model of rugged fitness landscapes and its application to maturation of the immune response. J Theor Biol. 1989 Nov 21;141(2):211–45. doi: 10.1016/S0022-5193(89)80019-0 2632988
38. Andersson DI, Hughes D, Antibiotic resistance and its cost: is it possible to reverse resistance? Nat Rev Microbiol. 2010 Apr;8(4):260–71. 20208551
39. Gisbert JP, Calvet X, O’Connor A, Mégraud F, O’Morain CA, Sequential therapy for Helicobacter pylori eradication: a critical review. J Clin Gastroenterol. 2010 May-Jun;44(5):313–25. 20054285
40. Hanazaki K, Antiviral therapy for chronic hepatitis B: a review. Curr Drug Targets Inflamm Allergy. 2004 Mar;3(1):63–70. doi: 10.2174/1568010043483908 15032642
41. Heenen S, Jacobs F, Vincent JL, Antibiotic strategies in severe nosocomial sepsis: Why do we not de-escalate more often? Crit Care Med. 2012 May;40(5):1404–9. 22430235
42. Khan AI, Dinh DM, Schneider D, Lenski RE, Cooper TF, Negative epistasis between beneficial mutations in an evolving bacterial population. Science. 2011 Jun 3;332(6034):1193–6. doi: 10.1126/science.1203801 21636772
43. Schenk MF, Szendro IG, Salverda ML, Krug J, de Visser JAGM, Patterns of epistasis between beneficial mutations in an antibiotic resistance gene. Mol Biol Evol. 2013 Aug;30(8):1779–87. doi: 10.1093/molbev/mst096 23676768
44. Hall DW, Agan M, Pope SC, Fitness epistasis among 6 biosynthetic loci in the budding yeast Saccharomyces cerevisiae. J Hered. 2010 Mar-Apr;101 Suppl 1:S75–84. doi: 10.1093/jhered/esq007 20194517
45. Lozovsky ER, Chookajorn T, Brown KM, Imwong M, Shaw PJ, Kamchonwongpaisan S, et al. Stepwise acquisition of pyrimethamine resistance in the malaria parasite. Proc Natl Acad Sci U S A. 2009 Jul 21; 106(29): 12025–12030. doi: 10.1073/pnas.0905922106 19587242
46. da Silva J, Coetzer M, Nedellec R, Pastore C, Mosier DE, Fitness epistasis and constraints on adaptation in a human immunodeficiency virus type 1 protein region. Genetics. 2010 May;185(1):293–303. doi: 10.1534/genetics.109.112458 20157005
47. Hinkley T, Martins J, Chappey C, Haddad M, Stawiski E, Whitcomb JM, et al. A systems analysis of mutational effects in HIV-1 protease and reverse transcriptase. Nat Genet. 2011 May;43(5):487–9. doi: 10.1038/ng.795 21441930
48. Woodford N, Ellington MJ, The emergence of antibiotic resistance by mutation. Clin Microbiol Infect. 2007 Jan;13(1):5–18. doi: 10.1111/j.1469-0691.2006.01492.x 17184282
49. Jensen SO, Lyon BR, Genetics of antimicrobial resistance in Staphylococcus aureus. Future Microbiol. 2009 Jun;4(5):565–82. doi: 10.2217/fmb.09.30 19492967
50. Lord CJ, Ashworth A, Mechanisms of resistance to therapies targeting BRCA-mutant cancers. Nat Med. 2013 Nov;19(11):1381–8. doi: 10.1038/nm.3369 24202391
51. Lito P, Rosen N, Solit DB, Tumor adaptation and resistance to RAF inhibitors. Nat Med. 2013 Nov;19(11):1401–9. doi: 10.1038/nm.3392 24202393
52. Orr HA, The genetic theory of adaptation: a brief history. Nat Rev Genet. 2005 Feb;6(2):119–27. doi: 10.1038/nrg1523 15716908
53. Kaznatcheev A. Complexity of evolutionary equilibria in static fitness landscapes; 2013. Preprint. Available: arXiv:13085094v1. Accessed 01 September 2013.
54. Weissman DB, Desai MM, Fisher DS, Feldman MW, The rate at which asexual populations cross fitness valleys. Theor Popul Biol. 2009 Jun;75(4):286–300. doi: 10.1016/j.tpb.2009.02.006 19285994
55. Iwasa Y, Michor F, Nowak MA, Stochastic tunnels in evolutionary dynamics. Genetics. 2004 Mar;166(3):1571–9. doi: 10.1534/genetics.166.3.1571 15082570
56. Nowak MA, What is a quasispecies? Trends Ecol Evol. 1992 Apr;7(4):118–21. doi: 10.1016/0169-5347(92)90145-2 21235976
57. Bull JJ, Meyers LA, Lachmann M, Quasispecies made simple. PLoS Comput Biol. 2005 Nov; 1(6): e61. doi: 10.1371/journal.pcbi.0010061 16322763
58. Moran PAP, et al. The statistical processes of evolutionary theory. Oxford, Clarendon Press; 1962.
59. Wright S, The roles of mutation, inbreeding, crossbreeding and selection in evolution. In: Proceedings of the Sixth International Congress on Genetics. vol. 1; 1932. pp. 356–366.
60. Fisher RA, The genetical theory of natural selection. Oxford, Clarendon Press; 1930.
61. Schaper S, Louis AA, The arrival of the frequent: how bias in genotype-phenotype maps can steer populations to local optima. PLoS One. 2014; 9(2): e86635. doi: 10.1371/journal.pone.0086635 24505262
62. Schaper S, Johnston IG, Louis AA, Epistasis can lead to fragmented neutral spaces and contingency in evolution. Proc Biol Sci. 2012 May 7;279(1734):1777–83. doi: 10.1098/rspb.2011.2183 22158953
63. Kouyos RD, Leventhal GE, Hinkley T, Haddad M, Whitcomb JM, Petropoulos CJ, et al. Exploring the complexity of the HIV-1 fitness landscape. PLoS Genet. 2012;8(3):e1002551. doi: 10.1371/journal.pgen.1002551 22412384
64. Volz EM, Pond SLK, Ward MJ, Brown AJL, Frost SDW, Phylodynamics of infectious disease epidemics. Genetics. 2009;183(4):1421–1430. doi: 10.1534/genetics.109.106021 19797047
65. Hamming RW, Error detecting and error correcting codes. Bell System Technical Journal. 1950;29(2):147–160. doi: 10.1002/j.1538-7305.1950.tb00463.x
66. Nowak MA, Komarova NL, Sengupta A, Jallepalli PV, Shih IM, Vogelstein B, et al. The role of chromosomal instability in tumor initiation.Proc Natl Acad Sci U S A. 2002 Dec 10;99(25):16226–31. doi: 10.1073/pnas.202617399 12446840
67. Komarova NL, Sengupta A, Nowak MA, Mutation–selection networks of cancer initiation: tumor suppressor genes and chromosomal instability. J Theor Biol. 2003 Aug 21;223(4):433–50. doi: 10.1016/S0022-5193(03)00120-6 12875822
68. Fontana W, Stadler PF, Bornberg-Bauer EG, Griesmacher T, Hofacker IL, Tacker M, et al. RNA folding and combinatory landscapes. Phys Rev E Stat Nonlin Soft Matter Phys. 1993 Mar;47(3):2083–2099. doi: 10.1103/PhysRevE.47.2083
69. Macken CA, Perelson AS, Protein evolution on rugged landscapes. Proc Natl Acad Sci U S A. 1989 Aug;86(16):6191–5. doi: 10.1073/pnas.86.16.6191 2762321
70. Macken CA, Hagan PS, Perelson AS, Evolutionary walks on rugged landscapes. SIAM J Appl Math. 1991;51(3):799–827. doi: 10.1137/0151040
71. Flyvbjerg H, Lautrup B, Evolution in a rugged fitness landscape. Phys Rev A. 1992;46(10):6714. doi: 10.1103/PhysRevA.46.6714 9907980
72. Gillespie JH, The causes of molecular evolution. Oxford University Press; 1991.
73. Grinstead CM, Snell JL, Introduction to Probability. American Mathematical Soc.; 1998.
74. Sella G, Hirsh AE, The application of statistical physics to evolutionary biology. Proc Natl Acad Sci U S A. 2005 Jul 5;102(27):9541–6. doi: 10.1073/pnas.0501865102 15980155